ATE462787T1 - Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington - Google Patents
Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntingtonInfo
- Publication number
- ATE462787T1 ATE462787T1 AT07290751T AT07290751T ATE462787T1 AT E462787 T1 ATE462787 T1 AT E462787T1 AT 07290751 T AT07290751 T AT 07290751T AT 07290751 T AT07290751 T AT 07290751T AT E462787 T1 ATE462787 T1 AT E462787T1
- Authority
- AT
- Austria
- Prior art keywords
- huntington
- disease
- treatment
- application
- type
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 230000002441 reversible effect Effects 0.000 title 1
- 230000006807 siRNA silencing Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 238000011808 rodent model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290751A EP2014769B1 (en) | 2007-06-18 | 2007-06-18 | Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE462787T1 true ATE462787T1 (de) | 2010-04-15 |
Family
ID=38476952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07290751T ATE462787T1 (de) | 2007-06-18 | 2007-06-18 | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8217018B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2014769B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5401451B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE462787T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2690730C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007005629D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009007855A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009135322A1 (en) * | 2008-05-09 | 2009-11-12 | The Universtity Of British Columbia | Methods and compositions for the treatment of huntington's disease |
| US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| AU2009323766B2 (en) | 2008-12-02 | 2016-10-06 | Wave Life Sciences Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
| SG177564A1 (en) | 2009-07-06 | 2012-02-28 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| WO2011097644A2 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP3321361B1 (en) | 2010-02-08 | 2019-03-27 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP2591356A1 (en) * | 2010-07-09 | 2013-05-15 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| DK2742135T4 (da) | 2011-08-11 | 2020-07-13 | Ionis Pharmaceuticals Inc | Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf |
| JP6490426B2 (ja) | 2012-02-29 | 2019-03-27 | サンガモ セラピューティクス， インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
| JP6246121B2 (ja) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
| JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | 不斉補助基 |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| WO2014062691A2 (en) * | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
| CN112080502A (zh) | 2013-10-11 | 2020-12-15 | Ionis制药公司 | 用于调节c9orf72表达的组合物 |
| MX391904B (es) * | 2013-11-11 | 2025-03-12 | Sangamo Biosciences Inc | Un represor genetico para usarse en el tratamiento de la enfermedad de huntington. |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| BR112016025849A2 (pt) * | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| PL3283080T3 (pl) | 2015-04-16 | 2020-07-27 | Ionis Pharmaceuticals, Inc. | Kompozycja do modulowania ekspresji c9orf72 |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
-
2007
- 2007-06-18 AT AT07290751T patent/ATE462787T1/de not_active IP Right Cessation
- 2007-06-18 EP EP07290751A patent/EP2014769B1/en not_active Not-in-force
- 2007-06-18 DE DE602007005629T patent/DE602007005629D1/de active Active
-
2008
- 2008-06-18 CA CA2690730A patent/CA2690730C/en not_active Expired - Fee Related
- 2008-06-18 JP JP2010512808A patent/JP5401451B2/ja not_active Expired - Fee Related
- 2008-06-18 US US12/665,137 patent/US8217018B2/en not_active Expired - Fee Related
- 2008-06-18 WO PCT/IB2008/002603 patent/WO2009007855A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010530239A (ja) | 2010-09-09 |
| WO2009007855A3 (en) | 2009-04-02 |
| US8217018B2 (en) | 2012-07-10 |
| US20100299768A1 (en) | 2010-11-25 |
| JP5401451B2 (ja) | 2014-01-29 |
| EP2014769A1 (en) | 2009-01-14 |
| EP2014769B1 (en) | 2010-03-31 |
| CA2690730C (en) | 2018-07-31 |
| CA2690730A1 (en) | 2009-01-15 |
| DE602007005629D1 (de) | 2010-05-12 |
| WO2009007855A2 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE462787T1 (de) | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington | |
| WO2006084209A3 (en) | Rnai expression constructs | |
| PL2257155T3 (pl) | Krioprezerwacja komórek i tkanek biologicznych | |
| ATE521711T1 (de) | In-vivo-screening-modelle zur behandlung der alzheimer-krankheit und anderer erkrankungen in zusammenhang mit dem qpct-gen | |
| EP2303292A4 (en) | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC | |
| WO2010017562A3 (en) | Induced pluripotent stem cells | |
| EP2414548A4 (en) | GENE EXPRESSION ANALYSIS IN SINGLE CELLS | |
| EP2250497A4 (en) | CELL PROCESSING AND / OR ENRICHMENT PROCESS | |
| WO2008144021A3 (en) | Ex vivo methods for validating substance testing with human organs and/or tissues | |
| WO2013158309A3 (en) | Non-disruptive gene targeting | |
| UY32361A (es) | Gen de delta-endotoxina axmi-150 y métodos de uso del mismo | |
| EP2207797A4 (en) | MODULATION OF THE SIRPALPHA CD47 INTERACTION TO IMPROVE TRANSPLANTATION OF HUMAN HEMATOPOETIC STEM CELLS AND COMPOUNDS THEREOF | |
| IN2009DN07390A (cg-RX-API-DMAC7.html) | ||
| EP2641911A3 (en) | Compositions and methods for re-programming cells without genetic modification | |
| FR2917975B1 (fr) | Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains | |
| WO2007064846A3 (en) | COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION | |
| WO2009047809A3 (en) | Sequence variants for inferring human pigmentation patterns | |
| EP1874922A4 (en) | METHOD USING STROMA CELLS FROM UMBILICAL CORD BLOOD TO DEVELOP AND GRAFT NUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD | |
| EP2285968A4 (en) | CHIMERIC COMPOSITIONS AND METHOD FOR REGULATING GENE EXPRESSION IN PLANTS | |
| BR112013007041A2 (pt) | animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação | |
| EP2325327A4 (en) | METHOD FOR ASSESSING SPECIFIC STORAGE OF D-GLUCOSE IN CELLS | |
| EP2222839A4 (en) | METHOD AND COMPOSITIONS FOR MODULATING THE DIFFERENTIATION OF PLURIPOTENTER CELLS | |
| CR8547A (es) | Composiciones y metodos relacionados con el cultivo de celulas madre neurales con celulas estromales de medula osea | |
| Čunderlíková | Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer | |
| EP2415868A4 (en) | METHOD AND KIT FOR EVALUATING OBESITY DEVELOPMENT PREDISPOSITION, ANTI-OBESITY AGENT AND SCREENING METHOD, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, PROCESS FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND 'ANTIBODY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |